Education
About Us
Working with TipRanks
Follow Us
Alkermes plc (ALKS)
NASDAQ:ALKS
ALKS Stock Chart & Stats
$28.15
-$0.20(-0.70%)
At close: 4:00 PM EST
$28.15
-$0.20(-0.70%)
Day’s Range― - ―
52-Week Range$25.17 - $36.32
Previous CloseN/A
Volume176.14K
Average Volume (3M)2.05M
Market Cap
$4.69B
Enterprise Value$3.64B
Total Cash (Recent Filing)$1.32B
Total Debt (Recent Filing)$70.00M
Price to Earnings (P/E)19.1
Beta0.77
Next Earnings
Apr 29, 2026EPS Estimate
-0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.29
Shares Outstanding166,649,930
10 Day Avg. Volume2,370,533
30 Day Avg. Volume2,051,135
Financial Highlights & Ratios
PEG Ratio-0.56
Price to Book (P/B)2.53
Price to Sales (P/S)3.12
P/FCF Ratio9.59
Enterprise Value/Market Cap0.78
Enterprise Value/Revenue2.47
Enterprise Value/Gross Profit2.86
Enterprise Value/Ebitda11.00
Forecast
1Y Price Target
$44.18Price Target Upside56.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-0.19
Revenue Forecast (FY)$1.79B
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentRegulatory alignment on the alixorexton pivotal trial design reduces development uncertainty and underpins a planned registrational program targeting broad labeling and multiple dosing options.
Commercial PerformanceLumryz's once-nightly dosing combined with favorable payer coverage supports stronger market adoption and helps sustain revenue from the sleep franchise.
Leadership SuccessionPlanned CEO succession to a long-tenured internal executive with the outgoing CEO remaining as chairman delivers leadership continuity and lowers transition risk.
Bears Say
Competitive RiskGeneric competition for legacy products and strong branded rivals may limit market share for oxybate therapies, constraining longer-term revenue potential.
Financial LeverageThe acquisition meaningfully increases company leverage, elevating financial risk until debt is reduced and profitability improves.
Revenue And Expense OutlookWeaker revenue guidance driven by softer product sales and rising operating expenses could pressure earnings and prompt downward revisions to forecasts.
Alkermes News
ALKS FAQ
What was Alkermes plc’s price range in the past 12 months?
Alkermes plc lowest stock price was $25.16 and its highest was $36.32 in the past 12 months.
What is Alkermes plc’s market cap?
Alkermes plc’s market cap is $4.69B.
When is Alkermes plc’s upcoming earnings report date?
Alkermes plc’s upcoming earnings report date is Apr 29, 2026 which is in 38 days.
How were Alkermes plc’s earnings last quarter?
Alkermes plc released its earnings results on Feb 25, 2026. The company reported $0.29 earnings per share for the quarter, missing the consensus estimate of $0.41 by -$0.12.
Is Alkermes plc overvalued?
According to Wall Street analysts Alkermes plc’s price is currently Undervalued.
Does Alkermes plc pay dividends?
Alkermes plc does not currently pay dividends.
What is Alkermes plc’s EPS estimate?
Alkermes plc’s EPS estimate is -0.43.
How many shares outstanding does Alkermes plc have?
Alkermes plc has 166,649,930 shares outstanding.
What happened to Alkermes plc’s price movement after its last earnings report?
Alkermes plc reported an EPS of $0.29 in its last earnings report, missing expectations of $0.41. Following the earnings report the stock price went down -7.038%.
Which hedge fund is a major shareholder of Alkermes plc?
Currently, no hedge funds are holding shares in ALKS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alkermes Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$44.18 (56.94% Upside)
$44.18 (56.94% Upside)
Blogger Sentiment
Bullish
ALKS Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 2.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.8%
Last 30 Days ▲ 1.6%
Last 30 Days ▲ 1.6%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-17.01%
12-Months-Change
Fundamentals
Return on Equity
14.45%
Trailing 12-Months
Asset Growth
23.09%
Trailing 12-Months
Company Description
Alkermes plc
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
ALKS Company Deck
ALKS Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a largely positive outlook driven by strong 2025 commercial performance (9% growth in proprietary portfolio), solid profitability and cash position, strategic acquisition of Avadel to enter sleep medicine (LUMRIZE), and clear pipeline momentum (elixorexant breakthrough designation and Phase 3 start). Key near‑term headwinds are acquisition accounting effects (inventory step‑up and amortization) producing an expected GAAP loss in 2026, materially higher R&D and SG&A to fund growth and integration, and financing‑related interest expense and debt. Management provided detailed 2026 guidance showing healthy adjusted EBITDA and revenue expansion, while acknowledging payer/competitive risks in the oxybate market and potential VIVITROL dynamics in 2027.View all ALKS earnings summariesALKS Revenue Breakdown
89.69% U.S.
10.24% Rest of world
0.07% Ireland
ALKS Stock 12 Month Forecast
Average Price Target
$44.18
▲(56.94% Upside)
Technical Analysis
Ownership Overview
1.42% Insiders
27.70% Mutual Funds
24.15% Other Institutional Investors
13.24% Public Companies and Individual Investors